Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Will Soriot Ditch AstraZeneca In Favor Of Teva… And A $20m Bonus?

Executive Summary

Pascal Soriot is reportedly about to abandon his top role at UK big pharma AstraZeneca to join Israel's generics giant Teva – a switch that could see him receive a $20m signing bonus, if the rumors are to be believed.

Advertisement

Related Content

Commercial Capsules: Soriot, IPOs, Deals And Hemophilia Data
Guide To The Turbulent Times At The Top of Teva
AstraZeneca Under Soriot: Progress Report
Teva CEO Steps Down While An Integration Hangs In The Balance
5 promises AstraZeneca must keep now Pfizer's gone

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC099129

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel